SCHEMBL1722185

SCHEMBL1722185

N[C@@H]1[C@H]2CNC[C@@H]12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22796032 1.00
SCHEMBL10067588 1.00
SCHEMBL3622835 1.00
SCHEMBL1026045 1.00
SCHEMBL21078303 1.00
SCHEMBL23379159 1.00
SCHEMBL2634306 1.00
SCHEMBL22249013 1.00
Hydrochloric Acid SCHEMBL30144936 0.96
SCHEMBL16775245 0.74 CCR5 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330250-B1 HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING BOEHRINGER INGELHEIM INT (DE) 2025-02-19 EP disclosed
US-12065427-B2 Heterocyclic compounds capable of activating STING BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-20 US disclosed
US-20240270718-A1 HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING BOEHRINGER INGELHEIM INT (DE) 2024-08-15 US disclosed
WO-2023274324-A9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海艾力斯医药科技股份有限公司 2023-10-26 WO disclosed
WO-2023274324-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海艾力斯医药科技股份有限公司 2023-01-05 WO disclosed
US-20220388986-A1 HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-12-08 US disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-10858360-B2 Tricyclic gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-08 US disclosed
WO-2020014269-A9 BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF BIOVINC, LLC. (US) 2020-03-05 WO disclosed
US-20170369498-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-12-28 US disclosed
US-20060217432-A1 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2006-09-28 US disclosed
US-20060128781-A1 Flavaxate derivatives as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2006-06-15 US disclosed
US-6956040-B2 Oxazolidinone piperazinyl derivatives as potential antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2005-10-18 US disclosed
EP-1572648-A1 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2005-09-14 EP disclosed
WO-2004052857-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2004-06-24 WO disclosed
US-6734307-B2 USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING RANBAXY LABORATORIES LIMITED (IN) 2004-05-11 US disclosed
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials MEHTA ANITA (IN) 2003-06-26 US disclosed
EP-0930297-B1 A process for preparing naphthyridones and intermediates PFIZER PROD INC (US) 2003-04-23 EP disclosed
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease RANBAXY LABORATORIES LIMITED (IN) 2002-08-01 US disclosed
US-6359137-B1 ANTIBIOTIC PFIZER INC. 2002-03-19 US disclosed